---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-107982"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:53:55.793420+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kodiak Sciences Q2 net loss $54.3M, cash $104.2M; pipeline milestones on track

## Summary
- Net loss of $54.3M ($1.03/share) vs $45.1M loss a year ago; R&D expenses rose to $42.8M.
- Cash and equivalents $104.2M; expected to fund operations into 2026.
- Tarcocimab Phase 3 GLOW2 topline data expected Q1 2026; DAYBREAK (wet AMD) topline in Q3 2026.
- KSI-101 Phase 1b MESI data: half of patients ≥15 letter gain at Week 12; Phase 3 enrolling.
- Investor R&D Day on July 16, 2025 presented 12-week KSI-101 data and commercial strategy.

## SEC filing metadata
- accession: 0000950170-25-107982
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000095017025107982/0000950170-25-107982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000095017025107982/kod-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-107982
- JSON: https://secwatch.observer/filing/0000950170-25-107982.json
- Plain text: https://secwatch.observer/filing/0000950170-25-107982.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.